Original Article Measuring Financial Toxicity Clinically Relevant PatientReported Outcome The Validation COmprehensive Score financial Toxicity COST Jonas A Souza MD MBA1 Bonnie J Yap MS1 Kristen Wroblewski MS2 Victoria Blinder MD MSc3 Fabiana S Aracid2ujo PhD4 Fay J Hlubocky PhD1 Lauren H Nicholas PhD5 Jeremy M OConnor MD1 Bruce Brockstein MD6 Mark J Ratain MD1 Christopher K Daugherty MD1 David Cella PhD7 BACKGROUND Cancer treatment lead increased financial distress patients To authors knowledge date stan dardized patientreported outcome measure validated assess distress METHODS Patients AJCC Stage IV solid tumors receiving chemotherapy 2 months recruited Financial toxicity measured COmprehensive Score financial Toxicity COST measure The authors collected data patient characteristics clinical trial participation health care use willingness discuss costs psychological distress Brief Profile Mood States POMS healthrelated quality life HRQOL measured Functional Assessment Cancer Therapy General FACTG European Organization Re search Treatment Cancer EORTC QOL questionnaires Testretest reliability internal consistency validity COST measure assessed standardscale construction techniques Associations resulting factors variables assessed multivariable analyses RESULTS A total 375 patients advanced cancer approached 233 621 agreed participate The COST measure demonstrated high internal consistency testretest reliability Factor analyses revealed coherent single latent variable financial toxicity COST values correlated income correlation coef ficient r 5 028 P001 psychosocial distress r 5 026 P001 HRQOL measured FACTG r 5 042 P001 EORTC QOL instruments r 5 033 P001 Independent factors associated financial toxicity race P 504 employment status P001 income P 5003 number inpatient admissions P 501 psychological distress P 5003 Will ingness discuss costs associated degree financial distress P 549 CONCLUSIONS The COST measure demonstrated reliability validity measuring financial toxicity Its correlation HRQOL indicates financial toxici ty clinically relevant patientcentered outcome Cancer 201712347684 VC 2016 The Authors Cancer published Wiley Periodi cals Inc behalf American Cancer Society This open access article terms Creative Commons Attribution NonCommercialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modifications adaptations KEYWORDS cost cancer financial burden financial toxicity patientreported outcome PRO INTRODUCTION Patients cancer confronted financial consequences cancer treatment include signifi outofpocket costs loss income caregiver burden12 The objective financial consequences cancer subjective financial concerns broadly termed financial toxicity34 This burden linked clinically relevant patient outcomes including healthrelated quality life HRQOL5 symptom burden6 compliance7 recently survival8 Within context current policies Patient Protection Affordable Care Act ACA newly sured patients expected higher cost share preferential enrollment highdeductible plans offer ing greater upfront affordability911 Combined escalating cancer costs highdeductible plans increase financial distress exacerbate disparities cancer care To abrogate impact financial distress Corresponding author Jonas A Souza MD MBA Department Medicine The University Chicago Medicine 5841 S Maryland Ave Chicago IL 60637 Fax 773 7023163 jdesouzachicagoboothedu 1Department Medicine The University Chicago Medicine Chicago Illinois 2Department Public Health Sciences The University Chicago Medicine Chica Illinois 3Center Health Policy Outcomes Memorial Sloan Kettering Cancer Center New York New York 4Institute Psychology Illinois Institute Technology Chicago IL 5Department Health Policy Management Johns Hopkins Bloomberg School Public Health Baltimore Maryland 6Department Medicine NorthShore University HealthSystem Evanston Illinois 7Department Medical Social Sciences Northwestern University Chicago Illinois We thank Jocelyn Herrera Kristen KippingJohnson Nancy Haefling support Additional supporting information online version article DOI 101002cncr30369 Received June 22 2016 Revised August 9 2016 Accepted September 8 2016 Published online October 7 2016 Wiley Online Library wileyonlinelibrarycom 476 Cancer February 1 2017 minimize potential augment disparities urgent need policy makers researchers clinicians accurately measure financial toxicity However best knowledge patientcentered toxicity rarely assessed clinical practice research12 The COmprehensive Score financial Toxicity COST patientreported outcome measure PROM previously developed Souza et al4 assess financial toxicity patients cancer In multistep process 155 patients advanced cancer interviewed velop 11item COST measure In response ur gent need tool instrument adopted clinical practice research establishment psychometric properties13 The current study examines COST measure respect psychometric prop erties measures construct The importance knowing properties empha sized US Food Drug Administration guidance PROMs recommended instru ments measurement properties established use14 Finally assess relevance clinical practice patientcentered research aimed evaluate patientreported financial toxicity correlated HRQOL MATERIALS AND METHODS Sample Patients eligible aged cid218 years diagnosis AJCC stage IV cancer regardless prior dis ease Patients receiving chemotherapy oral intravenous 2 months time interview Eastern Cooperative Oncology Group perfor mance status ECOG PS 0 2 approached participation Because goal current study determine instrument valid measuring financial concerns chose patients advanced dis ease receiving therapy 2 months sample likely received health care bills experienced financial issues Patients recruited 2 separate cancer centers The University Chicago Medicine The NorthShore University HealthSystem The study protocol approved local Institutional Review Boards patients provided formed consent Patients recruited May 2013 February 2015 Potential participants told general goal study learn factors affect experience cancer patient prospectively told specific objectives current study Measuring Financial Toxicityde Souza et al Measures Sociodemographic characteristics health care use willingness discuss costs Data related age sex education work status marital sta tus race ethnicity ECOG PS cancer type col lected We asked patients income sources previous year Household income measured function federal poverty level FPLThe FPL Health Insurance Marketplace cost assistance der ACA tax credit eligibility health insur ance ranges 138 400 FPL states decided expand Medicaid Financial toxicity mea sured COST measure Fig 14 Lower COST values indicate financial toxicity General mood disturbance psychological distress measured Brief Profile Mood States BriefPOMS15 Emergency department visits inpatient admissions 1 year inter view date collected measures health resource use To control different communication preferences related costs resulting bias responding questionnaires patients asked ing discuss costs medical team I like talk outofpocket health care costs test treatment recommend16 This question based seminal work Alexander et al assessment communication preferences16 Concurrent participation clinical trial time interview recorded patients taking clinical trials sponsible treatment costs HRQOL assessments HRQOL assessed 2 widely validated instruments Functional Assessment Cancer TherapyGeneral FACTG17 European Organization Research Treatment Cancers Quality Life Questionnaire global health status EORTCQOL18 We hypothesized higher financial toxicity mild moderate correlation worse HRQOL Psychometric analyses Guidelines International Society Pharmacoe conomics Outcomes Research ISPOR1920 COSMIN study COnsensusbased Standards se lection health Measurement PROM development followed The methods assess factor structure analysis available Supporting Information INstruments21 Reliability Validity The internal consistency COST measure gree individual items comprise scale Cancer February 1 2017 477 Original Article Figure 1 COmprehensive Score financial Toxicity COSTFunctional Assessment Chronic Illness Therapy FACIT Items 2 3 4 5 8 9 10 reverse scored The lower score worse financial toxicity measure latent variable assessed Cronbach Values 90 considered excellent In addition sample patients COST measure readministered 7day interval testretest The testretest reliability assessed intraclass correla tion coefficient ICC 1way random effects model Convergent validity assessed calculating Pearson correlation COST Brief POMS measures We hypothesized COST mea sure financial toxicity mild moderate statistically significant correlation Brief POMS measure psychological distress Similarly hy pothesized COST measure mild moderate statistically significant correlation income The rationale mild moderate correlations strong correlations conclude COST PROM actually measuring psychological distress HRQOL income financial toxici ty Divergent validity assessed correlations tween MarloweCrowne Social Desirability Scale MCSDS22 COST measure The MCSDS widely measure selfreported social desirability For validation purposes measures degree individuals attempt present favorable light We hypothesized financial toxicity 478 Cancer February 1 2017 statistically significant correlations social desir ability All instruments described Supporting Information Table 1 Factors Associated With Financial Toxicity Multivariable linear regression analyses performed compare average COST values obtained groups patients expected differ respect construct known groups validity The dependent vari able COST value Independent variables consid ered included patient sociodemographic characteristics cancer type length original diagnosis time original cancer diagnosis interview date health care use psychological distress communication preferen ces patient taking clinical trial Considering financial domain PROM included household income use health care resour ces potential implications costsharing loss income additional factors investigated We hypothesized individuals lower FPL groups worse financial toxicity patients higher health care use measured emergency partment visits inpatient admissions independent variables Statistical Analyses Differences participants nonparticipants regard baseline characteristics tested Student t tests chisquare tests appropriate The Pearson corre lation coefficient assess relation COST measure HRQOL In addition partial correla tions HRQOL calculated adjusting age23 ECOG PS24 variables signifi cantly associated financial toxicity multivariable analyses Correlations defined mild 020 039 moderate 040 059 strong tween 060 079 strong 080 10 A sample size 233 patients provided 80 power detect correlation coefficient 018 tween COST measure HRQOL instruments 2sided significance level 05 For testretest analysis sample size 20 patients assessed twice 7day period provided 80 power demonstrate excellent reliability25 ICC 075 assuming ICC null hypothesis 035 signifi cance level 05 In differential item functioning analyses Bonferroni correction control multiple comparisons P value threshold set 0045 On multivariable analyses variables included final model approaching statistical significance Measuring Financial Toxicityde Souza et al univariable analysis P10 substantial clinical trial participation willing ness discuss costs Interactions tested statistically significant included final model Missing data addressed instruments guidelines All analyses performed Stata statistical software version 13 StataCorp LP College Station Tex26 RESULTS Of 375 patients approached 236 629 agreed participate Reasons nonparticipation interested research 103 patients feeling 36 patients In addition 3 patients started survey withdrew consent financial notation leaving total 233 evaluable patients partici pation rate 621 Respondents likely younger average 5842 years vs 6321 years P001 married 733 vs 613 P 5 02 com pared nonrespondents Sex P 5 08 insurance sta tus P 5 07 race P 5 07 household income distribution P 5 07 demonstrate trend difference reach statistical signifi cance 05 level Data 142 patients 379 declined participation shown Online Supporting Information Table 2 Participants median age 59 years range 2788 years mean 6 standard deviation SD 5842 6 1147 years 58 patients female All health insurance coverage private purchased employer 62 followed Medi care supplementation 31 No patients acquired insurance ACA Marketplace The median length time cancer diagnosis 485 days range 569294 days The median house hold income 376 FPL range 07964 In addition 47 patients completed college achieved higher education 15 college education 51 patients having high school education The median COST value 23 range 044 mean 6 SD 2223 6 1189 Table 1 summarizes characteristics patients included analyses COST values Online Sup porting Information Table 3 describes primary tu mor types Online Supplementary Information Table 4 shows factor analysis results Reliability Validity The COST measure demonstrated excellent internal sistency Cronbach 92 The Cronbach alphas Cancer February 1 2017 479 Original Article TABLE 1 Patient Characteristics COST Valuesa Characteristic Institution The University Chicago NorthShore University HealthSystem Median age range y cid350 5164 6575 cid275 Sex Female Male Marital status Married Divorcedseparatedwidowed Never married Raceethnicity White nonHispanic African American Hispanic Other Asian Native American Education level Collegeb Some college technical training Completed college Graduate professional degree Insurance type Private employerbased Medicare supplementation Medicaid COBRA continuation coverage Employment status Working time time Unemployed Retired On shortterm longterm disability Others student homemaker ECOG performance status 0 1 2 Median length cancer diagnosis range cid31 y 1 y Median household income range poverty level cid3200 poverty level 200400 FPL 400600 FPL 600800 FPL 800 FPL Median inpatient admissions range cid32 cid23 Median emergency room visits range cid32 cid23 Median BriefPOMS range N 5 233 COST Mean6SDa Univariable P 199 854 34 146 59 2788 51 219 110 472 56 240 16 69 136 584 97 416 170 730 38 163 24 103 154 661 54 232 14 60 10 43 36 155 87 373 55 236 55 236 144 618 73 313 13 56 3 13 78 335 21 90 76 326 45 193 12 51 116 498 76 326 5 21 485 d 569294 d 90 386 143 614 3766 07964 27 116 83 356 50 215 21 90 24 103 1 012 156 669 41 176 0 07 187 803 10 43 14 150 2234 6 1179 2160 6 1265 2056 6 1171 2088 6 1184 2551 6 1098 2537 6 1401 2062 6 1157 2450 6 1202 2327 6 1186 2099 6 1186 1640 6 1067 2390 6 1221 1892 6 1071 1846 6 973 2154 6 1140 2220 6 1204 2028 6 1118 2229 6 1192 2529 6 1251 2189 6 1175 2447 6 1199 1531 6 814 1420 6 1917 2508 6 1185 1237 6 1072 2584 6 1081 1498 6 882 2669 6 949 2161 6 1189 2368 6 1127 1642 6 1557 2126 6 1190 2284 6 1189 1544 6 1003 2098 6 1077 2095 6 1301 2757 6 1128 3150 6 1001 2339 6 1146 1799 6 1226 2221 6 1176 2332 6 1322 74 05 01 02 03 11 04 001 26 32 001 009 77 001 Abbreviations COBRA Consolidated Omnibus Budget Reconciliation Act COST COmprehensive Score financial Toxicity ECOG Eastern Cooperative On cology Group FPL federal poverty level POMS Profile Mood States SD standard deviation Some percentages add 100 missing data Univariate P values derived linear regression models Lower COST values indicate higher toxicity b The category college education included 12 patients 51 completed junior high middle school 24 patients 103 com pleted high school 480 Cancer February 1 2017 males females comparable 92 91 spectively The testretest analysis revealed ICC 080 95 confidence interval 057092 The Pearson corre lation COST measure BriefPOMS 026 P001 indicating worse financial toxicity correlated higher psychological distress Not sur prisingly financial toxicity correlated household income 028 P001 indicating fi nancial toxicity lower COST values patients lower FPL groups With regard divergent validity association COST measure social sirability MCSDS near zero 011 statisti cally significant P 5 11 initially hypothesized TABLE 2 COST Values Willingness Discuss Costs Clinical Trial Status N 5 233 COST Mean 6 SD Univariable P Willing discuss costs care team Yes No unsure Clinical trial status 106 455 105 451 2254 6 1241 2142 6 1128 Yes No 65 279 168 721 2326 6 1192 2184 6 1189 49 41 Abbreviations COST COmprehensive Score financial Toxicity SD stan dard deviation Some percentages add 100 missing data Univariate P values derived linear regression models Lower COST values dicate higher toxicity Measuring Financial Toxicityde Souza et al employment final multivariable model Factors Associated With Financial Toxicity As shown Table 1 factors sociated financial toxicity univariable analyses Communication preferences clinical trial status significantly associated financial tox icity Table 2 However given theoretical impor tance assessing financial toxicity included potential confounders multivariable analyses In status P001 race P 5 04 household income P 5 003 psychological distress P 5 003 number patient admissions P 5 01 significant ly associated financial toxicity controlling age sex marital status insurance type clinical trial partic ipation communication preferences shown Table 3 It important note statistically signifi interactions including interaction tween employment income P 5 32 Nonwhite individuals tended lower COST scores worse fi nancial toxicity compared white individuals Simi larly unemployed patients lower COST scores compared groups reaching statistical signifi cance groups disability Higher psy chological distress values associated lower COST scores Those patients cid2 3 inpatient admis sions lower COST scores indicating worse financial toxicity nearly 6 points average compared TABLE 3 Factors Associated With COSTa Multivariate Analysesb Factor Raceethnicity White nonHispanic Hispanic African American Other Asian Native American Household income cid3200 FPL 200400 FPL 400600 FPL 600800 FPL 800 FPL Employment status Unemployed On shortterm longterm disability Working time Retired Others student homemaker No inpatient admissions cid32 cid23 Psychological distressBriefPOMS 1point increase Coefficient 95 CI Adjusted P Base 2241 2866 383 2514 2960 2067 2985 21982 012 Base 255 2285 795 361 2212 934 939 080 1798 1168 493 1844 Base 230 2404 865 958 303 1614 1069 358 1781 1261 371 2150 Base 2552 2987 2116 2034 2056 2012 04 003 001 01 003 Abbreviations 95 CI 95 confidence interval COST COmprehensive Score financial Toxicity FPL federal poverty level POMS Profile Mood States Lower COST values indicate higher toxicity b The multivariate model variables remained significant multivariate model presented table included variables P1 univariate analysis addition communication preferences clinical trial participation Cancer February 1 2017 481 Original Article fewer admissions In addition higher house hold income percentage FPL associated higher COST scores financial toxici ty 800 FPL nearly 12point higher mean COST score compared cid3200 FPL Financial Toxicity HRQOL The median FACTG value 79 range 23108 mean 6 SD 7701 6 1721 The median EORTC QOL value 66 range 0100 mean 6 SD 6151 6 2241 The Pearson correlation COST measure FACTG 042 P001 correla tion EORTCQOL 033 P001 When controlled age ECOG PS income psychological distress inpatient admissions employment status ethnicity correlations remained statistically signifi FACTG partial correlation 031 P001 EORTCQOL partial correlation 020 P001 confirming hypothesis financial toxicity correlated worse HRQOL DISCUSSION Using hypothesisbased approach1921 results current study validate COST measure measure financial toxicity specifically developed patients cancer We demonstrated statistically significant correlation HRQOL establishing clini cally relevant patientcentered measure The reported correlations BriefPOMS HRQOL income mild statistically significant hy pothesized These correlations add instruments va lidity demonstrates COSTPROM measuring psychosocial distress HRQOL income potentially observe strong strong correlations The identification factors associated financial toxicity equally important To best knowledge current study report relationship financial toxicity use health care resources We higher numbers inpatient admissions associated higher financial toxicity adjusted potentially confounding factors The importance inpatient admissions total health care costs demonstrated previously Chas tek et al27 demonstrated 55 total health care costs 6 months life related inpatient admissions However knowledge study Chastek et al address patients financial toxicity In current study demonstrated inpatient admissions impact financial toxicity individual patients The current study strengths First alyzed data individuals declined participa tion 3 patients withdrawing consent study assessing financial issues A major strength assessing potential confounders measuring financial toxicity We controlled psycho logical distress participation clinical trials results independent factors In addition communication preferences focus current study theoreti cal concern patients willingness discuss financial issues potentially introduce bias patients perspective topic selfreported COST assessment However willingness discuss fi nancial issues significantly associated COST values Finally instrument little rele vance correlated clinically meaningful comes Herein demonstrated financial toxicity measured COST measure correlated HRQOL measured 2 validated quantitative HRQOL instruments FACTG EORTCQOL adjusting potentially confounding factors A limitation current study study sample drawn tertiary referral health care cen ters participants form insurance cov known insured erage However patients face significant financial burdens especially insurance plan high deductibles patients risk exceeding lifetime limits10 In addition feasible extensively repeatedly interview patients poor ECOG PS limited sample patients ECOG PS 3 Also given crosssectional design assess financial toxicity related outofpocket costs loss produc tivity factors These limitations sidered perspective goal current study develop financial toxicity instrument identify populations risk drivers financial toxicity validation cohort We aimed demonstrate instrument measures designed measure Therefore objective cur rent study empirically demonstrate association financial toxicity measured instru ment wellknown social factors theory play role demonstrating validity instru ment In regard race income inpatient admissions employment status associated financial toxicity current study population 482 Cancer February 1 2017 measured COST instrument independent psy chological distress willingness discuss costs factors Underserved groups current study sample low income Af rican American individuals worse COST values likely findings current study replicated uninsured underinsured samples This hypothesis validated firmed future studies diverse insurance case mix specifically designed identify populations risk high school education population relatively underrepresented current study sample 51 Similarly differ ences regard drivers financial toxicity patients different cancer types examined drivers vary type disease type treatment Although toxicity thresholds analyzed validation sample quantita tive nature COST instrument allow prospective studies determine exact impact finan cial toxicity HRQOL comparison symp toms outcomes survival These prospective studies needed determine respon siveness change floor ceiling effects COSTPROM Finally objective cur rent study validate COSTPROM cap tured financial toxicity needed patients actually experience health care bills Therefore assessed patients stage IV disease receiv ing treatment 2 months chemotherapy unable conclude newly diagnosed patients provide similar results As society increasingly considers costs incurred patients cancer effect treatment instru ments measure financial toxicity patient centered scientifically derived clinically relevant The correlation HRQOL establishes financial toxici ty clinically relevant patientcentered measure The incorporation financial toxicity assessments obser vational research clinical trials ensure patient centered foundation evaluation financial distress FUNDING SUPPORT Supported grant University Chicago Institute Translation al MedicineClinical Translational Science Award UL1 TR000430 CONFLICT OF INTEREST DISCLOSURES Kristen Wroblewski received grant National Institutes HealthNational Cancer Institute P30 CA14599 work formed current study Mark J Ratain received Measuring Financial Toxicityde Souza et al equity cofounder PrescriptIQ personal fees multiple drug companies acting expert witness patent litigation personal fees AbbVie personal fees stock options Biscayne Pharmaceuticals grants Dicerna Pharmaceuticals personal fees Cantex Pharmaceuticals Genentech Kinex Pharmaceuticals Onconova Therapeutics Shionogi Xspray Agios Pharmaceuticals Cyclacel Drais Pharmaceuticals Circle Pharma Portola Pharmaceuticals Venaxis work performed outside current study In addition Dr Ratain patent related UGT1A1 genotyping irinotecan use royalties paid Mayo Clinic patent related genomic prescribing licensed PrescriptIQ AUTHOR CONTRIBUTIONS Jonas A Souza participated planning conducting interpret ing reporting guarantor study Bonnie J Yap Kristen Wroblewski Christopher K Daugherty David Cella participated planning conducting reporting study Victoria Blinder Fabiana S Aracid2ujo Fay J Hlubocky Lauren H Nicholas Jeremy M OConnor Bruce Brockstein Mark J Ratain participated interpretation reporting REFERENCES 1 Bestvina CM Zulling LL Rushing C et al Patientoncologist cost communication financial distress medication adherence J Oncol Pract 201410162167 2 Northouse L Williams Al Given B McCorkle R Psychosocial care family caregivers patients cancer J Clin Oncol 201230 12271234 3 Pollack A For profit industry seeks cancer drugs The New York Times September 1st 2009 httpwwwnytimescom20090902 healthresearch02cancerdrughtml Accessed September 20 2016 4 Souza JA Yap BJ Hlubocky FJ et al The development fi nancial toxicity patientreported outcome cancer COST mea sure Cancer 201412032453253 5 Zafar SY McNeil RB Thomas CM Lathan CS Ayanian JZ Provenzale D Populationbased assessment cancer survivors fi nancial burden quality study J Oncol Pract 201511145150 life prospective cohort 6 Lathan CS Cronin A TuckerSeeley R Zafar SY Ayanian JZ Schrag D Association financial strain symptom burden quality life patients lung colorectal cancer J Clin Oncol 20163417321740 7 Neugut AI Subar M Wilde ET et al Association prescrip tion copayment compliance adjuvant hormonal therapy women earlystage breast cancer J Clin Oncol 2011 2925342542 8 Ramsey SD Bansal A Fedorenko CR et al Financial insolvency risk factor early mortality patients cancer J Clin Oncol 201634980986 9 The Henry J Kaiser Family Foundation What actuarial values Affordable Care Act mean httpwwwkfforghealthreform upload8177pdf Accessed September 20 2016 10 Ungar L ODonnel J Dilemma deductibles costs crippling mid class httpwwwusatodaycomstorynewsnation20150101 dle middleclassworkersstruggletopayforcaredespiteinsurance19841 235 Accessed September 20 2016 11 Highdeductible health plans gamble rise tran script All Things Considered National Public Radio July 28 2013 httpwwwnprorg20130728206370593highdeductiblehealth plansgambleforsomeontherise Accessed September 20 2016 12 Zafar SY Peppercorn JM Schrag D et al The financial toxicity cancer treatment pilot study assessing outofpocket expenses insured cancer patients experience Oncologist 201318381390 Cancer February 1 2017 483 Original Article 13 Huntington SF Weiss BM Vogl DT et al Financial toxicity sured patients multiple myeloma crosssectional pilot study Lancet Haematol 20152e408e416 14 US Department Health Human Services FDA Center Drug Evaluation Research US Department Health Hu man Services FDA Center Biologics Evaluation Research US Department Health Human Services FDA Center Devices Radiological Health Guidance industry patient reported outcome measures use medical product development support labeling claims draft guidance Health Qual Life Outcomes 2006479 15 Cella DF Jacobsen PB Orav EJ Holland JC Silberfarb PM Rafla S A brief POMS measure distress cancer patients J Chronic Dis 198740939942 16 Alexander GC Casalino LP Meltzer DO Patientphysician commu nication outofpocket costs JAMA 2003290953958 17 Cella DF Tulsky DS Gray G et al The Functional Assessment Cancer Therapy scale development validation general measure J Clin Oncol 199311570579 18 Aaronson NK Ahmedzai S Bergman B et al The European Orga nization Research Treatment Cancer QLQC30 qualityoflife instrument use international clinical trials cology J Natl Cancer Inst 199385365376 19 Patrick DL Burke LB Gwaltney CJ et al Content validityestab lishing reporting evidence newly developed patient reported outcomes PRO instruments medical product evalua tion ISPOR PRO Good Research Practices Task Force report 1eliciting concepts new PRO instrument Value Health 2011 14967977 20 Patrick DL Burke LB Gwaltney CJ et al Content validityestab lishing reporting evidence newly developed patient reported outcomes PRO instruments medical product evalua tion ISPOR PRO Good Research Practices Task Force report 2assessing respondent understanding Value Health 201114978 988 21 Mokkink LB Terwee CB Patrick DL et al The COSMIN check list assessing methodological quality studies measure ment properties health status measurement instruments international Delphi study Qual Life Res 201019539549 22 Crowne DP Marlowe D A new scale social desirability indepen dent psychopathology J Consult Psychol 196024349354 23 Park BW Lee S Lee AR Lee KH Hwang SY Quality life differ ences younger older breast cancer patients J Breast Cancer 201114112118 24 Faller H Brahler E Harter M et al Performance status depres sive symptoms predictors quality life cancer patients A structural equation modeling analysis Psychooncology 201524 14561462 25 Streiner DL Norman GR Health Measurement Scales A Practical Guide Their Development Use 2nd ed New York Oxford University Press 1995 26 StataCorp LP Stata Statistical Software Release 13 College Station TX StataCorp LP 2013 27 Chastek B Harley C Kallich J Newcomer L Paoli CJ Teitelbaum AH Health care costs patients cancer end life J Oncol Pract 2012875s80s 484 Cancer February 1 2017